CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
The new online Learning Center with new content can still be found under the “Training” folder on ...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...